Skip to content

Study · Systematic review · n = 119 · 2024

6 results

Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis.

Vinciguerra F, Di Stefano C, Baratta R, Pulvirenti A, Mastrandrea G, Piazza L, Guccione F, Navarra G, Frittitta L

Obesity surgery6 Jan 2024Cited by 17 (Europe PMC)

PMID38183597 (opens in a new tab)PMCIDPMC10811090 (opens in a new tab)DOI10.1007/s11695-023-07053-9 (opens in a new tab)PepBankPUB-38183597
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

PurposePoor response to bariatric surgery, characterized by insufficient weight loss (IWL) or weight regain (WR), poses a significant challenge in obesity treatment. This study aims to assess the effectiveness of liraglutide in addressing this issue.Materials and methodsA retrospective, multicenter cohort study investigated the impact of liraglutide 3 mg on weight loss in adults with suboptimal responses or weight regain after bariatric surgery (BS). Additionally, a systematic review and meta-analysis were conducted for a comprehensive evaluation.ResultsA total of 119 patients (mean age 41.03 ± 11.2 years, 71.4% female) who experienced IWL or WR after BS received pharmacologic therapy with liraglutide 3 mg. Mean percent weight loss in the entire cohort was 5.6 ± 2.6% at 12 weeks and 9.3 ± 3.6% at 24 weeks with a significant reduction in waist circumference (p < 0.0001). No serious side effects were reported. A meta-analysis, utilizing the fixed effect model with the metafor package in R, included 6 and 5 papers for the change in body weight and BMI after liraglutide treatment, respectively. The analysis demonstrated a considerable reduction in body weight (7.9; CI - 10.4; - 5.4, p < 0.0001) and BMI (3.09; CI 3.89; - 2.28, p < 0.0001).ConclusionLiraglutide 3 mg emerges as a viable option for significant weight loss in patients experiencing IWL or WR after BS. Its inclusion in a multimodal, sequential obesity treatment approach proves promising.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a meta-analysis of 6 papers, liraglutide treatment was followed by a considerable reduction in body weight (7.9).

    In plain wordsIn pooled studies, body weight fell considerably after liraglutide treatment in people with poor response to bariatric surgery.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change in meta-analysis
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Reduction in body weight
    7.9 unit not stated
    meta-analysis, fixed effect

    Source sentences

    Summary
    The analysis demonstrated a considerable reduction in body weight (7.9; CI - 10.4; - 5.4, p < 0.0001) and BMI (3.09; CI 3.89; - 2.28, p < 0.0001).
    1 context sentence
    Summary · context
    A meta-analysis, utilizing the fixed effect model with the metafor package in R, included 6 and 5 papers for the change in body weight and BMI after liraglutide treatment, respectively.
  2. 02HumanSystematic reviewEfficacy outcome

    In a meta-analysis of 5 papers, liraglutide treatment was followed by a considerable reduction in BMI (3.09).

    In plain wordsIn pooled studies, body mass index fell considerably after liraglutide treatment in people with poor response to bariatric surgery.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI change in meta-analysis
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Reduction in BMI
    3.09 unit not stated
    meta-analysis, fixed effect

    Source sentences

    Summary
    The analysis demonstrated a considerable reduction in body weight (7.9; CI - 10.4; - 5.4, p < 0.0001) and BMI (3.09; CI 3.89; - 2.28, p < 0.0001).
    1 context sentence
    Summary · context
    A meta-analysis, utilizing the fixed effect model with the metafor package in R, included 6 and 5 papers for the change in body weight and BMI after liraglutide treatment, respectively.
  3. 03HumanObservational studyEfficacy outcome

    In adults with insufficient weight loss or weight regain after bariatric surgery, liraglutide 3 mg gave a mean weight loss of 5.6% at 12 weeks.

    In plain wordsIn adults with poor weight loss or weight regain after bariatric surgery, liraglutide 3 mg was linked to 5.6% weight loss at 12 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreasePercent weight loss at 12 weeks
    Study

    n = 119

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg · 12 weeksAs given in this study (human).

    Measurements

    Mean percent weight loss
    5.6%
    12 weeks

    Source sentences

    Summary
    Mean percent weight loss in the entire cohort was 5.6 ± 2.6% at 12 weeks
    2 context sentences
    Summary · context
    A retrospective, multicenter cohort study investigated the impact of liraglutide 3 mg on weight loss in adults with suboptimal responses or weight regain after bariatric surgery (BS).
    Summary · context
    A total of 119 patients (mean age 41.03 ± 11.2 years, 71.4% female) who experienced IWL or WR after BS received pharmacologic therapy with liraglutide 3 mg.
  4. 04HumanObservational studyEfficacy outcome

    In adults with insufficient weight loss or weight regain after bariatric surgery, liraglutide 3 mg gave a mean weight loss of 9.3% at 24 weeks.

    In plain wordsIn adults with poor weight loss or weight regain after bariatric surgery, liraglutide 3 mg was linked to 9.3% weight loss at 24 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreasePercent weight loss at 24 weeks
    Study

    n = 119

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mg · 24 weeksAs given in this study (human).

    Measurements

    Mean percent weight loss
    9.3%
    24 weeks

    Source sentences

    Summary
    Mean percent weight loss in the entire cohort was 5.6 ± 2.6% at 12 weeks and 9.3 ± 3.6% at 24 weeks
    2 context sentences
    Summary · context
    A retrospective, multicenter cohort study investigated the impact of liraglutide 3 mg on weight loss in adults with suboptimal responses or weight regain after bariatric surgery (BS).
    Summary · context
    A total of 119 patients (mean age 41.03 ± 11.2 years, 71.4% female) who experienced IWL or WR after BS received pharmacologic therapy with liraglutide 3 mg.
  5. 05HumanObservational studyEfficacy outcome

    In adults with insufficient weight loss or weight regain after bariatric surgery, liraglutide 3 mg was followed by a significant reduction in waist circumference.

    In plain wordsIn adults with poor weight loss or weight regain after bariatric surgery, waist size fell significantly during liraglutide 3 mg treatment.

    Peptide
    Liraglutide
    Outcome
    DecreaseWaist circumference
    Study

    n = 119

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3 mgAs given in this study (human).

    Source sentences

    Summary
    with a significant reduction in waist circumference (p < 0.0001).
    2 context sentences
    Summary · context
    A retrospective, multicenter cohort study investigated the impact of liraglutide 3 mg on weight loss in adults with suboptimal responses or weight regain after bariatric surgery (BS).
    Summary · context
    A total of 119 patients (mean age 41.03 ± 11.2 years, 71.4% female) who experienced IWL or WR after BS received pharmacologic therapy with liraglutide 3 mg.
  6. 06HumanObservational studySafety outcome

    In adults with insufficient weight loss or weight regain after bariatric surgery, no serious side effects were reported with liraglutide 3 mg.

    In plain wordsIn adults with poor weight loss or weight regain after bariatric surgery, no serious side effects were reported with liraglutide 3 mg.

    Peptide
    Liraglutide
    Outcome
    No significant changeSerious side effects
    Study

    n = 119

    Outcome group
    Adverse events · Whole body
    Studied dose
    3 mgAs given in this study (human).

    Source sentences

    Summary
    No serious side effects were reported.
    2 context sentences
    Summary · context
    A retrospective, multicenter cohort study investigated the impact of liraglutide 3 mg on weight loss in adults with suboptimal responses or weight regain after bariatric surgery (BS).
    Summary · context
    A total of 119 patients (mean age 41.03 ± 11.2 years, 71.4% female) who experienced IWL or WR after BS received pharmacologic therapy with liraglutide 3 mg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.